Literature DB >> 28640655

Usual Interstitial Pneumonia Can Be Detected in Transbronchial Biopsies Using Machine Learning.

Daniel G Pankratz1, Yoonha Choi1, Urooj Imtiaz1, Grażyna M Fedorowicz1, Jessica D Anderson1, Thomas V Colby2, Jeffrey L Myers3, David A Lynch4, Kevin K Brown5, Kevin R Flaherty6, Mark P Steele7, Steve D Groshong5, Ganesh Raghu8, Neil M Barth1, P Sean Walsh1, Jing Huang1, Giulia C Kennedy1, Fernando J Martinez9.   

Abstract

RATIONALE: Usual interstitial pneumonia (UIP) is the histopathologic hallmark of idiopathic pulmonary fibrosis. Although UIP can be detected by high-resolution computed tomography of the chest, the results are frequently inconclusive, and pathology from transbronchial biopsy (TBB) has poor sensitivity. Surgical lung biopsy may be necessary for a definitive diagnosis.
OBJECTIVES: To develop a genomic classifier in tissue obtained by TBB that distinguishes UIP from non-UIP, trained against central pathology as the reference standard.
METHODS: Exome enriched RNA sequencing was performed on 283 TBBs from 84 subjects. Machine learning was used to train an algorithm with high rule-in (specificity) performance using specimens from 53 subjects. Performance was evaluated by cross-validation and on an independent test set of specimens from 31 subjects. We explored the feasibility of a single molecular test per subject by combining multiple TBBs from upper and lower lobes. To address whether classifier accuracy depends upon adequate alveolar sampling, we tested for correlation between classifier accuracy and expression of alveolar-specific genes.
RESULTS: The top-performing algorithm distinguishes UIP from non-UIP conditions in single TBB samples with an area under the receiver operator characteristic curve (AUC) of 0.86, with specificity of 86% (confidence interval = 71-95%) and sensitivity of 63% (confidence interval = 51-74%) (31 test subjects). Performance improves to an AUC of 0.92 when three to five TBB samples per subject are combined at the RNA level for testing. Although we observed a wide range of type I and II alveolar-specific gene expression in TBBs, expression of these transcripts did not correlate with classifier accuracy.
CONCLUSIONS: We demonstrate proof of principle that genomic analysis and machine learning improves the utility of TBB for the diagnosis of UIP, with greater sensitivity and specificity than pathology in TBB alone. Combining multiple individual subject samples results in increased test accuracy over single sample testing. This approach requires validation in an independent cohort of subjects before application in the clinic.

Entities:  

Keywords:  idiopathic pulmonary fibrosis; interstitial lung diseases; molecular diagnostics

Mesh:

Year:  2017        PMID: 28640655     DOI: 10.1513/AnnalsATS.201612-947OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  19 in total

Review 1.  Molecular approach to the classification of chronic fibrosing lung disease-there and back again.

Authors:  Stijn E Verleden; Peter Braubach; Mark Kuehnel; Nicolas Dickgreber; Emily Brouwer; Pauline Tittmann; Florian Laenger; Danny Jonigk
Journal:  Virchows Arch       Date:  2020-11-09       Impact factor: 4.064

Review 2.  Defining Impaired Respiratory Health. A Paradigm Shift for Pulmonary Medicine.

Authors:  Paul A Reyfman; George R Washko; Mark T Dransfield; Avrum Spira; MeiLan K Han; Ravi Kalhan
Journal:  Am J Respir Crit Care Med       Date:  2018-08-15       Impact factor: 21.405

3.  Improving Care for Patients with Interstitial Lung Disease Using Machine Learning Requires Transparency and Reproducibility.

Authors:  Gary E Weissman
Journal:  Ann Am Thorac Soc       Date:  2017-12

Review 4.  Progress in Understanding and Treating Idiopathic Pulmonary Fibrosis.

Authors:  Jonathan A Kropski; Timothy S Blackwell
Journal:  Annu Rev Med       Date:  2019-01-27       Impact factor: 13.739

Review 5.  The state of the art for artificial intelligence in lung digital pathology.

Authors:  Vidya Sankar Viswanathan; Paula Toro; Germán Corredor; Sanjay Mukhopadhyay; Anant Madabhushi
Journal:  J Pathol       Date:  2022-06-20       Impact factor: 9.883

6.  Traction Bronchiectasis/Bronchiolectasis is Associated with Interstitial Lung Abnormality Mortality.

Authors:  Tomoyuki Hida; Mizuki Nishino; Takuya Hino; Junwei Lu; Rachel K Putman; Elias F Gudmundsson; Tetsuro Araki; Vladimir I Valtchinov; Osamu Honda; Masahiro Yanagawa; Yoshitake Yamada; Akinori Hata; Masahiro Jinzaki; Noriyuki Tomiyama; Hiroshi Honda; Raul San Jose Estepar; George R Washko; Takeshi Johkoh; David C Christiani; David A Lynch; Vilmundur Gudnason; Gunnar Gudmundsson; Gary M Hunninghake; Hiroto Hatabu
Journal:  Eur J Radiol       Date:  2020-05-18       Impact factor: 3.528

7.  Using Bronchoscopic Lung Cryobiopsy and a Genomic Classifier in the Multidisciplinary Diagnosis of Diffuse Interstitial Lung Diseases.

Authors:  Fayez Kheir; Ala Alkhatib; Gerald J Berry; Philip Daroca; Lisa Diethelm; Reinaldo Rampolla; Shigeki Saito; David L Smith; David Weill; Marjorie Bateman; Ramsy Abdelghani; Joseph A Lasky
Journal:  Chest       Date:  2020-05-25       Impact factor: 9.410

8.  Analytical performance of Envisia: a genomic classifier for usual interstitial pneumonia.

Authors:  Yoonha Choi; Jiayi Lu; Zhanzhi Hu; Daniel G Pankratz; Huimin Jiang; Manqiu Cao; Cristina Marchisano; Jennifer Huiras; Grazyna Fedorowicz; Mei G Wong; Jessica R Anderson; Edward Y Tom; Joshua Babiarz; Urooj Imtiaz; Neil M Barth; P Sean Walsh; Giulia C Kennedy; Jing Huang
Journal:  BMC Pulm Med       Date:  2017-11-17       Impact factor: 3.317

Review 9.  Impact of Transcriptomics on Our Understanding of Pulmonary Fibrosis.

Authors:  Milica Vukmirovic; Naftali Kaminski
Journal:  Front Med (Lausanne)       Date:  2018-04-04

Review 10.  Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response.

Authors:  Willis S Bowman; Gabrielle A Echt; Justin M Oldham
Journal:  Front Med (Lausanne)       Date:  2021-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.